Last reviewed · How we verify
Decrease Tocilizumab, Abatacept
At a glance
| Generic name | Decrease Tocilizumab, Abatacept |
|---|---|
| Also known as | Tocilizumab: Roactemra, Abatacept: Orencia |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Active Conventional Therapy Compared to Three Different Biologic Treatments in Early Rheumatoid Arthritis With Subsequent Dose Reduction (PHASE4)
- Dose Reduction for Early Rheumatoid Arthritis Patients With Low Disease Activity (PHASE4)
- TOward the Lowest Effective DOse of Abatacept or Tocilizumab (PHASE4)
- RETRO (REduction of Therapy in RA Patients in Ongoing Remission) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: